Classes
DEA Class; Rx
Common Brand Names; Persantine
- Antiplatelet Agents, Cardiovascular;
- Antiplatelet Agents, Hematologic
Description
Oral, P2Y12 platelet inhibitor
Used for rate reduction of myocardial infarction (MI) and stroke in patients with non-ST-elevation acute coronary syndromes, STEMI, established peripheral arterial disease, or recent MI or stroke
Associated with diminished antiplatelet effect in CYP2C19 poor metabolizers
Indications
Indicated for arterial thromboembolism prophylaxis.
Contraindications
Hypersensitivity
Thrombocytopenia
Adverse Effects
- Chest pain (20%)
- Angina exacerbation, IV (19.7%)
- Abnormal ECG (15.9%)
- Headache, IV (12.2%)
- Dizziness (12%)
- ST-T changes (7.5%)
- Abdominal discomfort, oral (6.1%)
- Extrasystole (5%)
- Nausea, IV (4.6%)
- Hypotension, IV (4.6%)
- Flushing (3.4%)
- Generalized pain (2.6%)
- Headache, oral (2.3%)
- Myocardial infarction (rare)
- Ventricular arrhythmia (rare)
- Bronchospasm (rare)
- Dyspnea
Warnings
FDA approval for chronic angina withdrawn (not useful according to most experts)
Dipyridamole has a vasodilatory effect and should be used with caution in patients with severe coronary artery disease (eg, unstable angina or recently sustained myocardial infarction); chest pain may be aggravated in patients with underlying coronary artery disease who are receiving drug
Elevations of hepatic enzymes and hepatic failure reported in association with therapy administration
Drug should be used with caution in patients with hypotension since it can produce peripheral vasodilation
Pregnancy and Lactation
Pregnancy Category: B
Lactation: enters breast milk; use with caution
Maximum Dosage
400 mg/day PO.
400 mg/day PO.
400 mg/day PO.
Specific maximum dosage information is not available.
How supplied
Dipyridamole
injectable solution
- 5mg/mL
tablet
- 25mg
- 50mg
- 75mg
